XNCR News and Press, Xencor Inc. From 02/23/21

Xencor (XNCR): Q4 GAAP EPS of -$0.24 beats by $0.12.Revenue of $41.85M (+1088.9% Y/Y) beats by $11.2M.Xencor expects to have cash to fund R&D programs and operations into 2024. Xencor expects to end 2021 with between $425-$475M in cash, cash equivalents and marketable securities.Shares +0...

-- Management to Host Conference Call at 4:30 p.m. ET Today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial resul...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release fourth quarter and full year 2020 financial results after the ma...

Adagene has filed to raise $132 million in a U.S. IPO. The firm is advancing antibody-based treatment candidates for various cancers. ADAG has a capable CEO but the firm is still ultra early stage and the IPO is priced well above the typical range for life science firms. I'll ...

Xencor (XNCR) and The University of Texas MD Anderson Cancer Center have entered strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibody cancer therapeutics.MD Anderson will identify and develop potential antibodies, and Xencor will apply its ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration and co...

Xencor (XNCR) has entered into a research collaboration and license agreement with Janssen Biotech to focus on the discovery of XmAb bispecific antibodies against CD28, an immune co-stimulatory receptor on T cells, and an undisclosed prostate tumor target, for the potential treatment of ...

-- Research collaboration focused on the discovery of novel bispecific antibodies directed toward the CD28 co-stimulatory receptor and an undisclosed prostate tumor target -- -- Xencor receives $50 million upfront payment and is eligible to receive potential milestone payments and a...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced updated data from its ongoing Phase 1 dose-escalation study of vibecotamab (XmAb ® 14045), a CD...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadThe week ahead will see investors once again weigh the brightening prospects for COVID-19 vaccines against a surging pand...